Myriad Genetics News

Myriad Genetics Settles Shareholder Lawsuits With Reforms

TipRanksNov 26 17:19 ET

Express News | Myriad Genetics Inc - Settlement Was Approved by the Court in Myriad Genetics, Inc. Stockholder Derivative Litigation

ReutersNov 26 16:56 ET

MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 V2

Zacks Nov 25 06:05 ET

Myriad Genetics Expands Partnership With Illumina to Enhance Genomic Profiling for Cancer Detection

Quiver QuantitativeNov 20 16:41 ET

Myriad Genetics Announces The Incorporation Of Its HRD Platform In Illumina's Updated Gene Panel Assay

BenzingaNov 20 16:33 ET

Myriad Genetics Announces Incorporation of Its Proprietary HRD Platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 V2

GlobeNewswireNov 20 16:30 ET

Myriad Genetics Announces Prequel Prenatal Screening Can Now Be Performed Eight Weeks Into Pregnancy

GlobeNewswireNov 19 08:00 ET

Morgan Stanley Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $21

Moomoo NewsNov 18 04:31 ET · Ratings

Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness

Seeking AlphaNov 15 15:55 ET

MYGN Stock Might Gain From SneakPeek Availability in Retail Stores

Zacks Nov 14 08:00 ET

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test With Retail Launch

GlobeNewswireNov 13 08:00 ET

Scotiabank Maintains Myriad Genetics(MYGN.US) With Buy Rating, Cuts Target Price to $24

Moomoo NewsNov 13 07:35 ET · Ratings

Earnings Release: Here's Why Analysts Cut Their Myriad Genetics, Inc. (NASDAQ:MYGN) Price Target To US$25.69

Simply Wall StNov 13 05:10 ET

Express News | Myriad Genetics Inc : Scotiabank Cuts Target Price to $24 From $34

ReutersNov 12 07:16 ET

Myriad Genetics Is Maintained at Neutral by Piper Sandler

Dow JonesNov 11 08:06 ET · Ratings

Myriad Genetics Analyst Ratings

BenzingaNov 11 07:55 ET · Ratings

J.P. Morgan Maintains Myriad Genetics(MYGN.US) With Sell Rating, Cuts Target Price to $15

Moomoo NewsNov 11 07:34 ET · Ratings

Piper Sandler Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $24

Moomoo NewsNov 11 07:34 ET · Ratings

Analysts Offer Insights on Healthcare Companies: Myriad Genetics (MYGN) and Jazz Pharmaceuticals (JAZZ)

TipRanksNov 11 07:16 ET · Ratings

Myriad Genetics: Overcoming Setbacks With Strategic Resilience and Growth Prospects

TipRanksNov 11 01:26 ET